Member Posts > Cardiol Therapeutics' (NASDAQ: CRDL) (TSX: CRDL)Bold Mission in Myocarditis Research
✔ An industry leader in inflammation-based cardiac therapies.
✔ Developing a first-in-class myocarditis treatment with CardiolRx™.
✔ Backed by extensive preclinical research and now in Phase II trials.
📌 2025 Trial Results Could Lead to a New Standard of Care
🔗 Learn more about CardiolRx™ and its clinical progress:

#MedicalResearch #CardiacBreakthrough